Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
On-demand versus prophylaxis BeneFIX in moderately severe to severe hemophilia B
2011-000520-15Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of coagulation factor ix recombinant in hemophilia B (HB) (2 arms), sponsored by Pfizer. Primary endpoint: Annualized number of bleeding episodes. Started Jul 2011; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-000520-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000520-15.